| 0 (0%) | 09-27 09:32 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2 |
1-year : | 2.34 |
| Resists | First : | 1.72 |
Second : | 2 |
| Pivot price | 1.44 |
|||
| Supports | First : | 1.36 |
Second : | 1.13 |
| MAs | MA(5) : | 1.61 |
MA(20) : | 1.38 |
| MA(100) : | 0.98 |
MA(250) : | 0.77 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 89.7 |
D(3) : | 89.5 |
| RSI | RSI(14): 75 |
|||
| 52-week | High : | 1.72 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LCTX ] has closed below upper band by 6.3%. Bollinger Bands are 110.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.72 - 1.73 | 1.73 - 1.74 |
| Low: | 1.49 - 1.5 | 1.5 - 1.51 |
| Close: | 1.7 - 1.71 | 1.71 - 1.72 |
Tue, 23 Sep 2025
Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial - Yahoo Finance
Fri, 12 Sep 2025
MAI Capital Management Cuts Stock Position in Lineage Cell Therapeutics, Inc. $LCTX - MarketBeat
Tue, 26 Aug 2025
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss - Business Wire
Thu, 14 Aug 2025
New Analyst Forecast: $LCTX Given 'Buy' Rating | LCTX Stock News - Quiver Quantitative
Wed, 13 Aug 2025
Lineage Cell Therapeutics Inc (LCTX) Q2 2025 Earnings Call Highlights: Strategic Partnerships ... - Yahoo Finance
Tue, 12 Aug 2025
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 228 (M) |
| Shares Float | 178 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 42.7 (%) |
| Shares Short | 27,240 (K) |
| Shares Short P.Month | 27,740 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | -178.7 % |
| Return on Assets (ttm) | -13.2 % |
| Return on Equity (ttm) | -71.6 % |
| Qtrly Rev. Growth | 96.4 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | -0.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -10.06 |
| PEG Ratio | 0 |
| Price to Book value | 8.14 |
| Price to Sales | 35.79 |
| Price to Cash Flow | -17.31 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 3.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|